Paper40934005
Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.
Tang XF and 9 others. Front Immunol, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin. Papers, record 40934005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40934005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, KIR | Major topic |
| Killer Cells, Natural | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| HLA Antigens | Major topic |
| Transplantation, Haploidentical | Major topic |
| Antilymphocyte Serum | Major topic |
| Humans | |
| Child | |
| Male | |
| Female | |
| Child, Preschool | |
| Adolescent | |
| Recurrence | |
| Retrospective Studies | |
| Infant | |
| Graft vs Host Disease |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19961944 | Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. | Biol Blood Marrow Transplant | 2010 | https://conductscience.org/library/papers/19961944 | PubMed |
| 2 | 38369017 | Donor KIR2DL1 Allelic Polymorphism Influences Posthematopoietic Progenitor Cell Transplantation Outcomes in the T Cell Depleted and Reduced Intensity Conditioning Setting. | Transplant Cell Ther | 2024 | https://conductscience.org/library/papers/38369017 | PubMed |
| 3 | 38629074 | Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight. | Front Immunol | 2024 | https://conductscience.org/library/papers/38629074 | PubMed |
| 4 | 29358179 | Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. | Blood | 2018 | https://conductscience.org/library/papers/29358179 | PubMed |
| 5 | 32267930 | Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. | Blood Adv | 2020 | https://conductscience.org/library/papers/32267930 | PubMed |
| 6 | 35242134 | KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection. | Front Immunol | 2022 | https://conductscience.org/library/papers/35242134 | PubMed |
| 7 | 20581313 | Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. | Blood | 2010 | https://conductscience.org/library/papers/20581313 | PubMed |
| 8 | 24748496 | Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. | J Immunol | 2014 | https://conductscience.org/library/papers/24748496 | PubMed |
| 9 | 27998801 | The impact of KIR2DS4 gene on clinical outcome after hematopoietic stem cell transplantation. | Hum Immunol | 2017 | https://conductscience.org/library/papers/27998801 | PubMed |
| 10 | 22139069 | Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. | Bone Marrow Transplant | 2012 | https://conductscience.org/library/papers/22139069 | PubMed |
| 11 | 24043749 | Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/24043749 | PubMed |
| 12 | 33542712 | Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. | Front Immunol | 2020 | https://conductscience.org/library/papers/33542712 | PubMed |
| 13 | 30787107 | Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. | J Immunol | 2019 | https://conductscience.org/library/papers/30787107 | PubMed |
| 14 | 18945967 | Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. | Blood | 2009 | https://conductscience.org/library/papers/18945967 | PubMed |
| 15 | 33767404 | Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. | Bone Marrow Transplant | 2021 | https://conductscience.org/library/papers/33767404 | PubMed |
| 16 | 38052043 | Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML. | Blood Adv | 2024 | https://conductscience.org/library/papers/38052043 | PubMed |
| 17 | 17268518 | Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. | Leukemia | 2007 | https://conductscience.org/library/papers/17268518 | PubMed |
| 18 | 36311784 | Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. | Front Immunol | 2022 | https://conductscience.org/library/papers/36311784 | PubMed |
| 19 | 28520526 | KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28520526 | PubMed |
| 20 | 22931314 | HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22931314 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42712389 | Contrasting relapse rate associated with the absence of HLA-A3/A11 in T cell-replete haploidentical transplantation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42712389 |
Source PubMed
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HLA-A | 3105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
| KIR2DS1 | 3806 | PubTator's text mining | https://conductscience.org/library/genes/3806 | NCBI Gene |
| KIR3DL2 | 3812 | PubTator's text mining | https://conductscience.org/library/genes/3812 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40934005
GET https://conductscience.org/api/papers/v1/40934005/references?page=2